文献速递临床生化质量管理与危急值

HbA1c分析创新:Tosoh GR01在速度与准确性间的平衡及作为IFCC次级参考测量程序的评估

Innovations in HbA1c analysis: finding the balance between speed and accuracy. An investigation of a potential new Secondary Reference Measurement Procedure for the IFCC.
PubMed 文献 · Clin Chem Lab Med · 2023-10-24

本研究评估Tosoh GR01两种操作模式(快速模式SM与长时模式LM)的分析性能,以判断其能否作为IFCC未来次级参考测量程序。采用CLSI EP协议评价精密度、准确性、线性、携带污染及血红蛋白变异体干扰。两种模式在46 mmol/mol和75 mmol/mol处CV均小于0.6%(SI单位),且通过NGSP和IFCC认证程序,Sigma大于6,除HbAE在HbA1c大于65 mmol/mol外无常见变异体干扰,表明其速度与准确性平衡良好,适合作为IFCC SRMP。

要点

  • Tosoh GR01两种模式在46和75 mmol/mol处CV均小于0.6%(SI单位),精密度高。
  • 与7种IFCC认证SRMP比较,两种模式均通过NGSP和IFCC认证程序。
  • 在50 mmol/mol处Sigma大于6,常见Hb变异体无干扰(HbAE在HbA1c大于65 mmol/mol除外)。

核心结论

  • Tosoh GR01两种分析模式在HbA1c测定中速度与准确性平衡良好,适合作为IFCC次级参考测量程序。

研究设计与样本

  • 采用CLSI评价协议EP-5、EP-9、EP-6、EP-10评估Tosoh GR01的精密度、准确性、线性、携带污染及血红蛋白变异体和其他潜在干扰。

主要发现

  • 两种模式在46 mmol/mol(6.4%)和75 mmol/mol(9.0%)处CV均小于0.6%(SI单位)和小于0.4%(NGSP单位)。
  • 与7种IFCC认证次级参考测量程序比较,两种模式均通过NGSP和IFCC认证程序。
  • 使用EP-5和EP-9结果在HbA1c 50 mmol/mol(6.7%)处Sigma大于6。
  • 除HbAE在HbA1c大于65 mmol/mol时外,两种模式对常见Hb变异体无干扰;快速模式可识别HbAS、HbAD和HbAC但不报告结果。

关键数值与推荐

  • 精密度:46 mmol/mol和75 mmol/mol处CV小于0.6%(SI单位)和小于0.4%(NGSP单位)。
  • 认证:与7种IFCC认证SRMP比较通过NGSP和IFCC认证程序。
  • Sigma:50 mmol/mol处大于6。
  • 干扰:HbAE在HbA1c大于65 mmol/mol时显示干扰;快速模式对HbAS、HbAD、HbAC识别但不报告结果。

临床怎么用

  • Tosoh GR01可用于快速HbA1c检测,两种模式均保持准确性,适合作为IFCC次级参考测量程序。
  • 遇到HbAE且HbA1c大于65 mmol/mol时需注意干扰可能。
  • 快速模式对HbAS、HbAD、HbAC可识别但不报告结果,需按实验室程序处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The escalating prevalence of diabetes worldwide has resulted in a dramatic increase in the number of people who need testing, which in turn necessitates faster HbA1c measurement. The Tosoh GR01 addresses the need for fast turnaround times of whilst offering pragmatic steps to maintain result accuracy in a single instrument by offering two distinct operating modes: Short Mode (SM) and Long Mode (LM). The aim of this study was to evaluate all relevant aspects of the performance of the Tosoh GR01 with a view to accepting the instrument as a future Secondary Reference Measurement Procedure (SRMP) for the IFCC. METHODS: Certified Clinical & Laboratory Standards Institute (CLSI) Evaluation Protocols (EP) were used to evaluate precision (EP-5), accuracy (EP-9), linearity (EP-6), carry-over (EP-10) and the effect of hemoglobin variants and other potential interferences. RESULTS: Both modes demonstrated CVs <0.6 % in SI units and <0.4 % in NGSP units at 46 mmol/mol (6.4 %) and 75 mmol/mol (9.0 %) and passed both National Glycohemoglobin Standardization Program (NGSP) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification procedures when compared with 7 IFCC Certified Secondary Reference Measurement Procedures (SRMP). Sigma for both modes was >6 when using the results of EP-5 and EP-9 at an HbA1c concentration of 50 mmol/mol (6.7 %). Neither mode showed any interference with common Hb-variants except for HbAE when HbA1c was >65 mmol/mol. In the SM HbAS, HbAD and HbAC were recognized but no result was reported. CONCLUSIONS: There is a good balance between speed and accuracy for determining HbA1c with the Tosoh GR01 in both analytical modes and the device is suitable for use as an IFCC SRMP.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Lenters-Westra E, English E. Innovations in HbA1c analysis: finding the balance between speed and accuracy. An investigation of a potential new Secondary Reference Measurement Procedure for the IFCC. Clin Chem Lab Med. 2023. PMID: 37870921. doi:10.1515/cclm-2023-1070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。